Use of beta-blockers and risk of serious upper gastrointestinal bleeding

a population-based case-control study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

85 Downloads (Pure)

Resumé

Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.

Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.

Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.

Conclusions: We found no association between beta-blocker use and UGIB.

OriginalsprogEngelsk
TidsskriftTherapeutic Advances in Gastroenterology
Vol/bind10
Udgave nummer12
Sider (fra-til)919-929
ISSN1756-283X
DOI
StatusUdgivet - 2017

Fingeraftryk

Case-Control Studies
Population
Odds Ratio
Denmark
Registries
Logistic Models

Citer dette

@article{4e9f4a31023b4ea69afeb7c0e7dde8b1,
title = "Use of beta-blockers and risk of serious upper gastrointestinal bleeding: a population-based case-control study",
abstract = "Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95{\%} CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.Conclusions: We found no association between beta-blocker use and UGIB.",
keywords = "Journal Article",
author = "Mette Reilev and Per Damkier and Lotte Rasmussen and Morten Olesen and {Thomsen Ernst}, Martin and Rish{\o}j, {Rikke Mie} and {Rix Hansen}, Morten and Anne Broe and Dastrup, {Alexander Steenberg} and Maja Hellfritzsch and Sidsel Arnspang and Anton Potteg{\aa}rd and Jesper Hallas",
year = "2017",
doi = "10.1177/1756283X17734116",
language = "English",
volume = "10",
pages = "919--929",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications",
number = "12",

}

TY - JOUR

T1 - Use of beta-blockers and risk of serious upper gastrointestinal bleeding

T2 - a population-based case-control study

AU - Reilev, Mette

AU - Damkier, Per

AU - Rasmussen, Lotte

AU - Olesen, Morten

AU - Thomsen Ernst, Martin

AU - Rishøj, Rikke Mie

AU - Rix Hansen, Morten

AU - Broe, Anne

AU - Dastrup, Alexander Steenberg

AU - Hellfritzsch, Maja

AU - Arnspang, Sidsel

AU - Pottegård, Anton

AU - Hallas, Jesper

PY - 2017

Y1 - 2017

N2 - Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.Conclusions: We found no association between beta-blocker use and UGIB.

AB - Background: Some studies indicate a reduced risk of serious upper gastrointestinal bleeding (UGIB) for users of beta-blockers, but the association remains to be confirmed in larger studies and characterized with respect to differences among beta-blockers. We aimed to assess whether beta-blocker use decreases the risk of UGIB.Methods: We conducted a register-based, population-based case-control study in Denmark. We identified cases with a first validated discharge diagnosis of UGIB during the period 1995-2006. Controls were selected by risk-set sampling in a ratio of 10:1. We estimated crude and adjusted odds ratios (ORs) of the association between current beta-blocker use and the risk of UGIB by using conditional logistic regression and further stratified by selective and non-selective beta-blockers, respectively.Results: We identified 3571 UGIB cases and 35,582 controls. Use of beta-blockers was not found to be associated with a decreased risk of UGIB (adjusted OR 1.10; 95% CI: 1.00-1.21). The association remained neutral after stratification by selective and non-selective beta-blockers, and by single beta-blocker substances. Similarly, we found no association between current beta-blocker use and the risk of UGIB within different subgroups.Conclusions: We found no association between beta-blocker use and UGIB.

KW - Journal Article

U2 - 10.1177/1756283X17734116

DO - 10.1177/1756283X17734116

M3 - Journal article

VL - 10

SP - 919

EP - 929

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 12

ER -